Su questa pagina
LSTA Lisata Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 6, 2026
$1,47
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$0,99minimo 52 sett.
$5,07massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$13M
P/E (TTM)
-0.9
EPS (TTM)
$-1.64
Ricavi (TTM)
$100.0K
i tuoi badge
Intervallo 52 sett.
$1–$5
Rating Analisti
BUY
Prezzo Obiettivo
$4
P/E
-0.9
ROE
-99.9%
Margine di Profitto Netto
-14621.0%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
LSTA Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$1.47
Capitalizzazione di Mercato (MRQ)
$13M
P/E (TTM)
-0.9
EPS (TTM)
$-1.64
Ricavi (TTM)
$100.0K
ROE (TTM)
-99.9%
Intervallo 52 sett.
$1–$5
LSTA Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Split azionari
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 15 Settembre 2022 | 1-for-15 | Inverso |
| 28 Luglio 2016 | 1-for-10 | Inverso |
| 16 Luglio 2013 | 1-for-10 | Inverso |
| 09 Agosto 2007 | 1-for-10 | Inverso |
| 31 Agosto 2006 | 1-for-10 | Inverso |
Informazioni su Lisata Therapeutics, Inc. - Common Stock Panoramica della società da Wikipedia
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide (also known as iRGD and CEND-1), orphan drug status in pancreatic cancer, followed by a Fast track (FDA) status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.
== References ==
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaBiotechnology
dipendenti21
paeseUS
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$170.0K2016-12-31 → 2025-12-31
EPS$-1.912016-12-31 → 2025-12-31
Flusso di cassa libero·2016-12-31 → 2023-12-31
Margine netto-14621.0%2016-12-31 → 2024-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | LSTA | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -0.9media 5 anni ≈-1.0 | ≈-1.0 | · | · | |
| P/S (TTM) | 134.0 | · | · | · | |
| P/B (MRQ) | 1.6media 5 anni ≈0.5 | ≈0.5 | · | · | |
| Prezzo / FCF (TTM) | -1.1 | · | · | · | |
| Prezzo / Flusso di cassa (TTM) | -1.1media 5 anni ≈-1.1 | ≈-1.1 | · | · | |
| Prezzo / Valore contabile tangibile (MRQ) | 1.7media 5 anni ≈2.2 | ≈2.2 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | LSTA | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | -16428.0% | · | · | · | |
| Margine ante imposte (TTM) | -15008.0% | · | · | · | |
| Margine di Profitto Netto (TTM) | -14621.0% | · | · | · | |
| ROA (TTM) | -80.8%media 5 anni ≈-47.0% | ≈-47.0% | -106.4% | Di prim'ordine | |
| ROE (TTM) | -99.9%media 5 anni ≈-52.0% | ≈-52.0% | -135.0% | Di prim'ordine |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | LSTA | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Rapporto corrente (MRQ) | 3.7media 5 anni ≈8.5 | ≈8.5 | 4.3 | Bassa liquidità |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | LSTA | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | -83.0% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | LSTA | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue / Employee (Ricavi / Dipendente) | ≈$8.1K | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
14.0%
Prossimo report
Nov 04, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Settembre 2025 | $-0.49 | $-0.55 | 10.2% | |
| 30 Giugno 2025 | $-0.54 | $-0.66 | 18.6% | |
| 31 Marzo 2025 | $-0.55 | $-0.54 | -1.7% | |
| 31 Dicembre 2024 | $-0.55 | $-0.78 | 29.1% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.0K | $1M | $0 | $0 | · | · | · | · | · | $35M | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | $31M | |
| R&D Expense | · | · | · | · | $18M | $9M | $11M | $8M | $16M | $17M | |
| SG&A Expense | $10M | $12M | $13M | $14M | $11M | $10M | $9M | $9M | $12M | $13M | |
| Operating Expenses | $18M | $23M | $26M | $58M | $29M | $19M | $20M | $17M | $28M | $30M | |
| Operating Income | $-18M | $-22M | $-26M | $-58M | $-29M | $-19M | $-20M | $-17M | $-28M | $-30M | |
| Interest Expense | · | · | · | · | · | · | $0 | $5.0K | $378.0K | $2M | |
| Other Non-op | $-145.0K | $-257.0K | $-186.0K | $-155.0K | $-75.0K | $0 | $740.0K | $824.0K | $273.0K | $23.9K | |
| Pretax Income | $-18M | $-21M | $-23M | $-57M | $-29M | $-19M | $-19M | $-16M | $-28M | $-31M | |
| Income Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-12M | $0 | |
| Net Income | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| EPS (Basic) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | $-1.67 | $2.56 | $-4.99 | |
| EPS (Diluted) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | · | $2.56 | $-4.99 | |
| Shares (Basic) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| Shares (Diluted) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| EBITDA | · | $-22M | $-26M | $-58M | · | $-19M | $-20M | $-17M | $-27M | $-30M |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $16M | $23M | $32M | $25M | $17M | $14M | $10M | $29M | $7M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $26M | $0 | |
| Receivables | $0 | $900.0K | $0 | · | · | · | · | · | $234.5K | $138.8K | |
| Prepaid Expense | $2M | $2M | $3M | $3M | $1M | $758.0K | $815.0K | $1M | $1M | $2M | |
| Current Assets | $18M | $35M | $54M | $72M | $96M | $35M | $26M | $44M | $61M | $25M | |
| PP&E (Net) | $18.0K | $72.0K | $175.0K | $296.0K | $62.0K | $57.0K | $100.0K | $165.0K | $257.0K | $705.4K | |
| PP&E (Gross) | $494.0K | $661.0K | $661.0K | $713.0K | $430.0K | $370.0K | $349.0K | $349.0K | $1M | $2M | |
| Accum. Depreciation | $476.0K | $589.0K | $486.0K | $417.0K | $368.0K | $313.0K | $249.0K | $184.0K | $832.0K | $1M | |
| Goodwill | · | · | · | · | · | · | · | · | · | $7M | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $0 | · | · | · | · | $2M | |
| Other Non-current Assets | $23.0K | $160.0K | $332.0K | $528.0K | $764.0K | $614.0K | $1M | $309.0K | $2M | $2M | |
| Total Assets | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Accounts Payable | $1M | $1M | $2M | $3M | $2M | $1M | $1M | $762.0K | $1M | $2M | |
| Accrued Liabilities | $2M | $4M | $4M | $4M | $3M | $2M | $4M | $5M | $8M | $3M | |
| Short-term Debt | · | · | · | · | · | · | · | $0 | $159.0K | $563.8K | |
| Current Liabilities | $3M | $6M | $7M | $6M | $5M | $4M | $6M | $6M | $9M | $21M | |
| Capital Leases | $0 | $0 | $137.0K | $305.0K | $485.0K | $254.0K | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $1M | |
| Other Non-current Liabilities | $72.0K | $72.0K | $210.0K | $327.0K | $485.0K | $254.0K | $624.0K | $2M | $4M | $389.9K | |
| Total Liabilities | $3M | $6M | $7M | $7M | $5M | $4M | $7M | $7M | $13M | $30M | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $6M | |
| Total Debt | · | · | · | · | · | · | · | $0 | $159.2K | $6M | |
| Common Stock | $9.0K | $8.0K | $8.0K | $8.0K | $4.0K | $19.0K | $11.0K | $10.0K | $9.0K | $8.2K | |
| Paid-in Capital | $580M | $578M | $577M | $575M | $546M | $459M | $439M | $436M | $433M | $410M | |
| Retained Earnings | $-565M | $-548M | $-528M | $-507M | $-453M | $-426M | $-417M | $-398M | $-382M | $-405M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $707.6K | |
| AOCI | $-37.0K | $-81.0K | $-42.0K | $-29.0K | $-70.0K | $-13.0K | $2.0K | $-32.0K | $-28.0K | $0 | |
| Stockholders' Equity | $15M | $30M | $48M | $67M | $92M | $32M | $21M | $38M | $51M | $5M | |
| Liabilities + Equity | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Shares Outstanding | 8,833,875 | 8,410,000 | 8,151,000 | 7,867,000 | 3,986,000 | 1,292,000 | 10,517,609 | 9,865,735 | 9,483,911 | 8,205,790 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146.0K | $174.0K | $189.0K | $69.0K | $55.0K | $100.0K | $100.0K | $200.0K | $400.0K | $500.0K | |
| Stock-based Comp | $1M | $2M | $2M | · | · | · | · | · | · | · | |
| Deferred Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-576.0K | $0 | |
| Amort. of Intangibles | $65.0K | $71.0K | $71.0K | $21.0K | · | · | · | · | · | $570.0K | |
| Other Non-cash | · | · | $3M | $35M | · | $10M | $379.0K | $-4M | $-44M | $8M | |
| Operating Cash Flow | $-16M | $-19M | $-20M | $-21M | $-22M | $-9M | $-19M | $-20M | $-21M | $-24M | |
| CapEx | $28.0K | $0 | $0 | $285.0K | $60.0K | $20.0K | $0 | $134.0K | $135.0K | $1M | |
| Investing Cash Flow | $15M | $13M | $10M | $29M | $-55M | $-7M | $21M | $-5M | $41M | $-3M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | $-6M | $-9M | |
| Stock Issued | $844.0K | $68.0K | $321.0K | $43.0K | $86M | $19M | · | · | · | · | |
| Net Stock Activity | · | $68.0K | $321.0K | $43.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $599.0K | $-206.0K | $385.0K | $-224.0K | $85M | $19M | $1M | $824.0K | $-932.0K | $21M | |
| Net Change in Cash | $-253.0K | $-6M | $-10M | $8M | $8M | $2M | $4M | $-24M | · | $-6M | |
| Taxes Paid | $6.0K | $6.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | $-20M | $-21M | · | $-9M | $-19M | $-20M | $-21M | $-27M | |
| Levered FCF | · | · | · | · | · | · | $-19M | $-20M | $-21M | $-28M |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -2240.9% | · | · | · | · | · | · | · | -88.8% | |
| Net Margin | · | -1998.5% | · | · | · | · | · | · | · | -94.4% | |
| Pretax Margin | · | -2078.3% | · | · | · | · | · | · | · | -94.0% | |
| EBITDA Margin | · | -2240.9% | · | · | · | · | · | · | · | -83.7% | |
| ROA | · | -44.6% | -32.6% | -63.8% | · | -25.8% | -54.0% | -29.9% | 39.3% | -57.9% | |
| ROE | · | -51.4% | -36.3% | -68.3% | · | -30.6% | -66.1% | -36.6% | 83.0% | -232.9% | |
| ROIC | · | -72.9% | -48.0% | -82.7% | · | -25.2% | -96.5% | -45.0% | -31.8% | -276.4% |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 6.2 | 8.2 | 11.3 | · | 10.1 | 4.3 | 7.8 | 6.6 | 1.3 | |
| Quick Ratio | · | 3.0 | 3.4 | 5.0 | · | 4.7 | 2.3 | 1.8 | 5.9 | 0.9 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.0 | 0.0 | 1.3 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | 0.5 | |
| Interest Coverage | · | · | · | · | · | · | · | -3397.4 | -73.0 | -16.9 |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | · | · | · | · | · | · | 0.6 | |
| Receivables Turnover | · | 2.2 | · | · | · | · | · | · | · | 12.9 |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $3.52 | $5.91 | $8.46 | · | $1.68 | $1.98 | $3.82 | $5.33 | $0.60 | |
| Revenue / Share | · | $0.12 | $0.00 | · | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-2.32 | $-2.48 | $-4.09 | · | · | · | $-2.06 | $-2.33 | · | |
| Cash / Share | · | $1.93 | $2.77 | $4.09 | · | $0.85 | $1.33 | $1.04 | $3.08 | $1.79 | |
| EPS (TTM) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | · | $2.56 | $-4.99 |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -83.0% | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $170.0K | $1M | $0 | $0 | $33M | $33M | $33M | $33M | $33M | $35M | |
| Net Income TTM | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| Market Cap | · | $25M | $22M | $20M | · | $416M | $396M | $527M | $499M | $348M | |
| Enterprise Value | · | · | · | · | · | · | · | $517M | $444M | $340M | |
| P/E | -1.0 | -1.2 | -1.1 | -0.2 | -1.7 | -40.5 | · | · | 20.6 | -8.5 | |
| P/S | · | 25.1 | · | · | · | 12.6 | 12.0 | 15.9 | 15.1 | 9.9 | |
| P/B | · | 0.8 | 0.5 | 0.3 | · | 12.8 | 19.0 | 14.0 | 9.9 | 71.3 | |
| P / Tangible Book | 1.1 | 0.9 | 0.5 | 0.3 | 8.2 | 12.8 | · | · | · | · | |
| P / Cash Flow | · | -1.3 | -1.1 | -0.9 | · | -47.1 | -21.0 | -26.4 | -23.9 | -14.7 | |
| P / FCF | · | · | -1.1 | -0.9 | · | -47.0 | -21.0 | -26.2 | -23.8 | -13.1 | |
| EV / EBITDA | · | · | · | · | · | · | · | -30.8 | -16.3 | -11.5 | |
| EV / FCF | · | · | · | · | · | · | · | -25.7 | -21.2 | -12.8 | |
| EV / Revenue | · | · | · | · | · | · | · | 15.6 | 13.5 | 9.6 | |
| Earnings Yield | -102.7% | -80.5% | -94.5% | -413.8% | -59.1% | -2.5% | · | · | 4.9% | -11.8% |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $100.0K | $0 | $70.0K | $0 | $1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $3M | $4M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $4M | |
| Operating Expenses | $4M | $5M | $3M | $4M | $5M | $6M | $6M | $5M | $6M | $7M | $6M | $6M | $7M | $7M | $7M | $38M | |
| Operating Income | $-4M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-6M | $-7M | $-6M | $-6M | $-7M | $-7M | $-7M | $-38M | |
| Other Non-op | $984.0K | $-54.0K | $-15.0K | $-18.0K | $-7.0K | $-105.0K | $-11.0K | $-45.0K | $-14.0K | $-187.0K | $-12.0K | $-11.0K | $-150.0K | $-13.0K | $-7.0K | $0 | |
| Pretax Income | $-3M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-5M | $-6M | $-5M | $-5M | $-6M | $-6M | $-6M | $-37M | |
| Income Tax | $0 | $-387.0K | $0 | $0 | $0 | $-962.0K | $0 | $0 | $0 | $-798.0K | $0 | $0 | $-2M | $0 | $0 | $0 | |
| Net Income | $-3M | $-4M | $-3M | $-4M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-4M | $-6M | $-6M | $-37M | |
| EPS (Basic) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| EPS (Diluted) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| Shares (Basic) | 9,106,000 | 9,006,000 | · | 8,738,000 | 8,605,000 | 8,602,000 | · | 8,321,000 | 8,308,000 | 8,294,000 | · | 8,141,000 | 8,021,000 | 7,987,000 | · | 4,747,000 | |
| Shares (Diluted) | 9,106,000 | 9,006,000 | · | 8,738,000 | 8,605,000 | 8,602,000 | · | 8,321,000 | 8,308,000 | 8,294,000 | · | 8,141,000 | 8,021,000 | 7,987,000 | · | 4,747,000 | |
| EBITDA | $-4M | $-5M | · | $-4M | $-5M | $-6M | · | $-5M | $-6M | $-7M | · | $-6M | $-7M | $-7M | · | $-38M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $13M | $16M | $19M | $17M | $20M | $16M | $20M | $28M | $22M | $23M | $32M | $24M | $28M | $32M | $31M | |
| Receivables | · | · | $0 | · | · | · | $900.0K | · | · | · | $0 | · | · | · | · | · | |
| Prepaid Expense | $570.0K | $960.0K | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $3M | $3M | $4M | $4M | $3M | $2M | |
| Current Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $42M | $48M | $54M | $57M | $61M | $65M | $72M | $77M | |
| PP&E (Net) | $14.0K | $16.0K | $18.0K | $22.0K | $48.0K | $74.0K | $72.0K | $96.0K | $119.0K | $146.0K | $175.0K | $204.0K | $233.0K | $262.0K | $296.0K | $299.0K | |
| PP&E (Gross) | $494.0K | $494.0K | $494.0K | $494.0K | $566.0K | $689.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $713.0K | · | |
| Accum. Depreciation | $480.0K | $478.0K | $476.0K | $472.0K | $518.0K | $615.0K | $589.0K | $565.0K | $542.0K | $515.0K | $486.0K | $457.0K | $428.0K | $399.0K | $417.0K | · | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $352.0K | |
| Other Non-current Assets | $0 | $23.0K | $23.0K | $23.0K | $70.0K | $116.0K | $160.0K | $201.0K | $246.0K | $290.0K | $332.0K | $371.0K | $410.0K | $449.0K | $528.0K | $588.0K | |
| Total Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Accounts Payable | $836.0K | $510.0K | $1M | $619.0K | $782.0K | $602.0K | $1M | $556.0K | $728.0K | $1M | $2M | $1M | $775.0K | $1M | $3M | $974.0K | |
| Accrued Liabilities | $2M | $3M | $2M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | |
| Current Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $4M | $5M | $7M | $5M | $4M | $5M | $6M | $6M | |
| Capital Leases | · | · | $0 | · | · | · | $0 | $0 | $47.0K | $92.0K | $137.0K | $181.0K | $223.0K | $265.0K | $305.0K | $345.0K | |
| Other Non-current Liabilities | $50.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $119.0K | $164.0K | $210.0K | $253.0K | $295.0K | $337.0K | $327.0K | $367.0K | |
| Total Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $5M | $5M | $7M | $5M | $5M | $6M | $7M | $7M | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | |
| Paid-in Capital | $581M | $581M | $580M | $580M | $579M | $579M | $578M | $578M | $578M | $577M | $577M | $576M | $576M | $575M | $575M | $574M | |
| Retained Earnings | $-572M | $-569M | $-565M | $-562M | $-557M | $-553M | $-548M | $-543M | $-539M | $-533M | $-528M | $-523M | $-517M | $-513M | $-507M | $-501M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | |
| AOCI | $-17.0K | $-21.0K | $-37.0K | $-42.0K | $-50.0K | $-78.0K | $-81.0K | $-32.0K | $-77.0K | $-104.0K | $-42.0K | $-100.0K | $-50.0K | $-52.0K | $-29.0K | $-90.0K | |
| Stockholders' Equity | $8M | $11M | $15M | $17M | $21M | $25M | $30M | $34M | $38M | $43M | $48M | $53M | $58M | $61M | $67M | $72M | |
| Liabilities + Equity | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Shares Outstanding | 9,119,004 | 9,107,291 | 8,833,875 | 8,755,948 | 8,626,464 | 8,620,162 | 8,408,844 | 8,319,600 | 8,321,061 | 8,307,433 | 8,149,897 | 8,139,449 | 8,132,357 | 7,998,342 | 7,866,061 | 7,862,602 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.0K | $2.0K | $15.0K | $44.0K | $44.0K | $43.0K | $41.0K | $42.0K | $45.0K | $46.0K | $47.0K | $47.0K | $47.0K | $48.0K | · | $8.0K | |
| Stock-based Comp | $214.0K | $364.0K | · | · | $239.0K | $530.0K | · | · | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $0 | $0 | $12.0K | $18.0K | $18.0K | $17.0K | $18.0K | $18.0K | $18.0K | $17.0K | $17.0K | $18.0K | $18.0K | $18.0K | $18.0K | · | |
| Operating Cash Flow | $-3M | $-3M | $-3M | $-3M | $-4M | $-5M | $-5M | $-3M | $-5M | $-7M | $-4M | $-4M | $-4M | $-8M | $-6M | $-4M | |
| CapEx | $0 | $0 | $0 | $0 | $0 | $28.0K | $0 | $0 | $0 | $0 | · | $0 | · | · | $26.0K | $24.0K | |
| Investing Cash Flow | $0 | $0 | $0 | $5M | $505.0K | $9M | $1M | $-6M | $12M | $6M | $-6M | $12M | $-725.0K | $4M | $7M | $2M | |
| Stock Issued | $29.0K | $0 | $205.0K | $353.0K | $74.0K | $212.0K | $36.0K | $0 | $32.0K | $0 | $24.0K | $0 | · | · | $14.0K | $0 | |
| Net Stock Activity | · | $0 | · | · | · | $212.0K | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $29.0K | $181.0K | $205.0K | $353.0K | $64.0K | $-23.0K | $-96.0K | $0 | $32.0K | $-142.0K | $24.0K | $-6.0K | $452.0K | $-85.0K | $14.0K | $-99.0K | |
| Net Change in Cash | $-3M | $-3M | $-3M | $2M | $-3M | $4M | $-3M | $-9M | $6M | $-788.0K | $-10M | $9M | $-4M | $-4M | $676.0K | $-2M | |
| Free Cash Flow | · | $-3M | · | · | · | $-5M | · | · | · | · | · | · | · | · | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -16.2% | -20.9% | · | -14.2% | -13.8% | -12.2% | · | -10.2% | -9.6% | -9.4% | · | -7.7% | -5.4% | -7.8% | · | -41.3% | |
| ROE | -20.0% | -24.8% | · | -16.6% | -15.7% | -13.8% | · | -11.4% | -10.5% | -10.4% | · | -8.4% | -5.7% | -8.3% | · | -43.8% | |
| ROIC | -48.4% | -41.6% | · | -25.4% | -23.2% | -19.2% | · | -15.8% | -14.4% | -13.4% | · | -11.3% | -7.5% | -11.2% | · | -52.4% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | · | 4.7 | 5.8 | 7.5 | · | 8.0 | 9.4 | 8.9 | · | 11.2 | 14.1 | 12.4 | · | 12.1 | |
| Quick Ratio | 3.5 | 3.9 | · | 4.2 | 3.9 | 5.3 | · | 4.2 | 6.3 | 4.1 | · | 6.3 | 5.4 | 5.3 | · | 4.9 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.90 | $1.20 | · | $1.98 | $2.44 | $2.94 | · | $4.05 | $4.60 | $5.18 | · | $6.51 | $7.13 | $7.62 | · | $9.16 | |
| Revenue / Share | $0.00 | $0.00 | · | $0.00 | $0.01 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | · | $-0.34 | · | · | · | $-0.63 | · | · | · | $-0.85 | · | · | · | $-1.03 | · | · | |
| Cash / Share | $1.15 | $1.43 | · | $2.17 | $1.95 | $2.35 | · | $2.34 | $3.40 | $2.62 | · | $3.98 | $2.91 | $3.52 | · | $4.00 | |
| EPS (TTM) | $-1.64 | $-1.86 | · | $-2.13 | $-2.23 | $-2.30 | · | $-2.51 | $-2.57 | $-2.46 | · | $-1.82 | $-9.05 | $-10.19 | · | $-15.99 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $100.0K | $170.0K | · | $1M | $1M | $1M | · | $0 | $0 | $0 | · | $0 | $0 | · | · | · | |
| Net Income TTM | $-15M | $-16M | · | $-18M | $-19M | $-19M | · | $-21M | $-21M | $-20M | · | $-21M | $-54M | $-56M | · | $-55M | |
| Market Cap | $31M | $46M | · | $23M | $25M | $20M | · | $25M | $29M | $26M | · | $17M | $30M | $26M | · | $36M | |
| P/E | -2.1 | -2.7 | · | -1.2 | -1.3 | -1.0 | · | -1.2 | -1.4 | -1.3 | · | -1.2 | -0.4 | -0.3 | · | -0.3 | |
| P/S | 310.0 | 268.4 | · | 21.4 | 23.4 | 20.3 | · | · | · | · | · | · | · | · | · | · | |
| P/B | 3.8 | 4.2 | · | 1.3 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Tangible Book | 4.0 | 4.3 | · | 1.4 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Cash Flow | · | -14.8 | · | · | · | -3.8 | · | · | · | -3.7 | · | · | · | -3.2 | · | · | |
| Earnings Yield | -48.2% | -37.1% | · | -81.3% | -76.9% | -97.9% | · | -83.7% | -74.1% | -78.8% | · | -85.0% | -244.6% | -313.5% | · | -345.4% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | $170.0K | $1M | $0 | $0 | · |
| Margine Operativo % | · | -2240.9% | · | · | · |
| Utile netto | $-17M | $-20M | $-21M | $-54M | $-27M |
| EPS Diluito | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rapporto corrente | · | 6.2 | 8.2 | 11.3 | · |
| Quick Ratio | · | 3.0 | 3.4 | 5.0 | · |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | · | · | $-20M | $-21M | · |
Proprietari istituzionali (13F) 34 filer · $4.1M totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
34
Valore detenuto
$4.1M
Nuove posizioni
3
Posizioni chiuse
5
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 3 (-11 vs trimestre precedente) | 5 (+1 vs trimestre precedente) | 9 (+4 vs trimestre precedente) | 5 (+2 vs trimestre precedente) | +32K |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $948.046 | 278.837 | 23,31% | Azioni |
| VANGUARD GROUP INC | $503.891 | 270.909 | 12,39% | Azioni |
| Yakira Capital Management, Inc. | $471.107 | 138.561 | 11,58% | Azioni |
| CSS LLC/IL | $375.435 | 110.422 | 9,23% | Azioni |
| DELTEC ASSET MANAGEMENT LLC | $282.870 | 83.197 | 6,96% | Azioni |
| Rangeley Capital, LLC | $275.400 | 81.000 | 6,77% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $246.999 | 72.632 | 6,07% | Azioni |
| BlackRock, Inc. | $186.514 | 54.857 | 4,59% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $166.478 | 48.964 | 4,09% | Azioni |
| GTS SECURITIES LLC | $102.680 | 30.200 | 2,52% | Azioni |
| STATE STREET CORP | $86.183 | 25.348 | 2,12% | Azioni |
| JANE STREET GROUP, LLC | $63.720 | 18.741 | 1,57% | Azioni |
| CITADEL ADVISORS LLC | $52.839 | 15.541 | 1,30% | Azioni |
| NORTHERN TRUST CORP | $52.816 | 15.534 | 1,30% | Azioni |
| JBF Capital, Inc. | $48.780 | 14.347 | 1,20% | Azioni |
| Cerity Partners LLC | $41.422 | 12.183 | 1,02% | Azioni |
| BANK OF AMERICA CORP /DE/ | $35.200 | 10.353 | 0,87% | Azioni |
| HighTower Advisors, LLC | $34.143 | 10.042 | 0,84% | Azioni |
| SOL Capital Management CO | $29.342 | 12.175 | 0,72% | Azioni |
| COOK WEALTH MANAGEMENT GROUP LLC | $29.342 | 12.175 | 0,72% | Azioni |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $16.800 | 5.000 | 0,41% | Azioni |
| Founders Capital Management | $5.668 | 1.667 | 0,14% | Azioni |
| Vanguard Global Advisers, LLC | $3.512 | 1.033 | 0,09% | Azioni |
| Connective Capital Management, LLC | $3.454 | 1.016 | 0,08% | Azioni |
| Tower Research Capital LLC (TRC) | $2.468 | 726 | 0,06% | Azioni |
| OSAIC HOLDINGS, INC. | $680 | 200 | 0,02% | Azioni |
| Caitong International Asset Management Co., Ltd | $306 | 90 | 0,01% | Azioni |
| MORGAN STANLEY | $255 | 75 | 0,01% | Azioni |
| BARCLAYS PLC | $238 | 70 | 0,01% | Azioni |
| Virtu Financial LLC | $200 | 58.782 | 0,00% | Azioni |
| SBI Securities Co., Ltd. | $24 | 7 | 0,00% | Azioni |
| Cheviot Value Management, LLC | $10 | 3 | 0,00% | Azioni |
| Fortitude Family Office, LLC | $3 | 1 | 0,00% | Azioni |
| ROYAL BANK OF CANADA | $0 | 52 | 0,00% | Azioni |
Attivisti e proprietari del 5%+ 20 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| RimAsia Capital Partners, L.P., RimAsia Capital Partners GP, L.P., RimAsia Capital Partners GP, Ltd., Eric H.C. Wei ×8 depositi | 20 Maggio 2010 | · | Deposito iniziale | Investimento passivo | SEC |
| Robin L. Smith | 10 Settembre 2009 | · | Deposito iniziale | Investimento passivo | SEC |
| Catherine M. Vaczy | 10 Settembre 2009 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 16 Novembre 2007 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 30 Ottobre 2007 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 20 Febbraio 2007 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 05 Gennaio 2007 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 15 Dicembre 2006 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 29 Giugno 2006 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata | 29 Giugno 2006 | · | Deposito iniziale | Investimento passivo | SEC |
| Mark Weinreb | 29 Giugno 2006 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 28 Giugno 2006 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 08 Dicembre 2005 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata | 31 Agosto 2005 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 04 Agosto 2005 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata | 02 Agosto 2005 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 02 Agosto 2005 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 01 Agosto 2005 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 29 Aprile 2005 | · | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata | 23 Settembre 2004 | · | Deposito iniziale | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 51 insider · 29 dirigenti · 17 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Joseph Talamo | SVP and CFO | 13 Gennaio 2020 A | 59.644 | 0 | 0 | $0 |
| Robert S Vaters | President & CFO | 12 Agosto 2015 P | 228.750 | 0 | 0 | $0 |
| Robert Dickey IV | Chief Financial Officer | 31 Dicembre 2014 A | 12.066 | 0 | 0 | $0 |
| Larry Alan May | Chief Financial Officer | 02 Gennaio 2013 A | 64.618 | 0 | 0 | $0 |
| David W. Slack | President & CBO | 09 Gennaio 2023 A | 20.642 | 0 | 0 | $0 |
| Hans Keirstead | President of the Issuer's NeoStem Oncology, LLC subsidiary. | 09 Maggio 2014 A | · | 0 | 0 | $0 |
| Ian Zhang | President and Managing Director, NeoStem (China), Inc. | 04 Aprile 2011 A | 10.000 | 0 | 0 | $0 |
| Mark Weinreb | President | 21 Maggio 2009 A | 66.923 | 0 | 0 | $0 |
| Robert Joseph Aholt JR | Chief Operating Officer | 03 Ottobre 2005 A | 4.369.317 | 0 | 0 | $0 |
| Tariq Imam | SVP, Bus Dev, General Counsel | 09 Gennaio 2026 A | 36.078 | 0 | 0 | $0 |
| James Nisco | SVP, Fin/Treas, Chief Actg Off | 09 Gennaio 2026 A | 32.311 | 0 | 0 | $0 |
| Kristen K Buck | EVP, R&D and CMO | 09 Gennaio 2026 A | 93.462 | 0 | 0 | $0 |
| Todd C Girolamo | CLO, SVP of Corp Dev | 14 Gennaio 2022 F | 160.827 | 0 | 0 | $0 |
| Douglas W Losordo | Executive Vice President, Global Head of Research and Development and Chief Medical Officer | 13 Gennaio 2020 A | 130.406 | 0 | 0 | $0 |
| Robin L Smith | Executive Chair of the Board | 02 Giugno 2015 A | 347.285 | 0 | 0 | $0 |
| Catherine M Vaczy | General Counsel | 13 Aprile 2015 A | 71.234 | 0 | 0 | $0 |
| Stephen W Potter | Executive Vice President | 31 Dicembre 2014 A | 14.016 | 0 | 0 | $0 |
| Robert Dillman | Vice President, Oncology of the Issuer. The Reporting Person also serves as Chief Medical Officer of the Issuer's NeoStem Oncolo | 09 Maggio 2014 A | · | 0 | 0 | $0 |
| Martin E Schmieg | Vice President - Corporate Dev | 25 Giugno 2012 A | · | 0 | 0 | $0 |
| Jonathan Sackner-Bernstein | VP Clinical Dev & Reg Affairs | 02 Aprile 2012 A | · | 0 | 0 | $0 |
| Jason Kolbert | VP of Strategic Business Development | 04 Gennaio 2012 A | 8.000 | 0 | 0 | $0 |
| Mingsheng Shi | Chairman of the Board of Directors of Suzhou Erye Pharmaceutical Company Ltd., an entity 51%-owned by the Company. | 04 Gennaio 2012 A | 3.650.770 | 0 | 0 | $0 |
| Alan G Harris | Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs | 04 Aprile 2011 A | · | 0 | 0 | $0 |
| Anthony Salerno | Vice President, Operations and Academic Affairs Exhibit List Exhibit 24 - Power of Attorney | 09 Giugno 2010 A | · | 0 | 0 | $0 |
| Jian M Zhang | Vice President, Pharmaceutical Operations, and General Manager of Suzhou Erye Pharmaceuticals Company Ltd., a 51% owned subsidi | 09 Giugno 2010 A | 3.650.770 | 0 | 0 | $0 |
| Christopher C Duignan | Vice President, Finance | 30 Novembre 2009 A | · | 0 | 0 | $0 |
| Lepore Teresa Linn Samuels | VP of Sales and Marketing | 29 Ottobre 2009 A | · | 0 | 0 | $0 |
| Renee Cohen | VP of Oper. & Corp. Strategy | 27 Febbraio 2008 A | 31.000 | 0 | 0 | $0 |
| Wayne A Marasco | Senior Scientific Advisor | 02 Giugno 2006 A | 1.436.713 | 0 | 0 | $0 |
| Cynthia Schwalm | Direttore | 09 Gennaio 2026 A | 95.446 | 0 | 0 | $0 |
| Steven M Klosk | Direttore | 09 Gennaio 2026 A | 95.815 | 0 | 0 | $0 |
| Anne Clem Whitaker | Direttore | 10 Gennaio 2022 A | 182.635 | 0 | 0 | $0 |
| Michael H. Davidson | Direttore | 10 Gennaio 2022 A | 209.753 | 0 | 0 | $0 |
| MYERS STEVEN S | Direttore | 10 Gennaio 2022 A | 212.269 | 0 | 0 | $0 |
| Eric Wei | Direttore | 07 Febbraio 2017 S | 172.223 | 0 | 0 | $0 |
| Richard J Berman | Direttore | 09 Gennaio 2017 A | 7.177 | 0 | 0 | $0 |
| Andrew L Pecora | Direttore | 22 Giugno 2016 A | 393.784 | 0 | 0 | $0 |
| Drew Bernstein | Direttore | 02 Giugno 2015 A | 10.000 | 0 | 0 | $0 |
| Martyn D Greenacre | Direttore | 02 Giugno 2015 A | 88.531 | 0 | 0 | $0 |
| Edward Geehr | Direttore | 29 Giugno 2012 A | · | 0 | 0 | $0 |
| Joseph Zuckerman | Direttore | 21 Maggio 2009 A | 41.260 | 0 | 0 | $0 |
| RimAsia Capital Partners Manager, Ltd. | Proprietario del 10% | 17 Settembre 2012 S | 105.306 | 0 | 0 | $0 |
| Fullbright Finance Ltd | Proprietario del 10% | 28 Dicembre 2009 P | 3.250.770 | 0 | 0 | $0 |
| Gregory B Brown | · | 09 Gennaio 2026 A | 95.659 | 0 | 0 | $0 |
| David J Mazzo | · | 09 Gennaio 2026 A | 311.890 | 0 | 0 | $0 |
| Mohammad Azab | · | 09 Gennaio 2026 A | 104.925 | 0 | 0 | $0 |
| Heidi Henson | · | 09 Gennaio 2026 A | 85.725 | 0 | 0 | $0 |
| Erkki Ruoslahti | · | 09 Gennaio 2023 A | 20.000 | 0 | 0 | $0 |
| Peter G Traber | · | 10 Gennaio 2022 A | 149.190 | 0 | 0 | $0 |
| Robert A Preti | · | 18 Maggio 2017 F | 33.786 | 0 | 0 | $0 |
| Aholt Jr Family Trust | · | 05 Giugno 2006 S | 12.352.227 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 4 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 80.444 SH | 19 Agosto 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 191.371 SH | 19 Agosto 2026 | Giornaliero |
| DFSU · Dimensional ETF Trust | 0,00% | 100 NS | 31 Luglio 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 8 NS | 31 Luglio 2026 | N-PORT |
LSTA Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 9 analisti
COMPRA
Target mediano
$4.00
+172,1%
2 22,2%
Acquisto forte
4 44,4%
Compra
3 33,3%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
1 analisti · 2026-07-19Target medio $4.00 +172,1%
Basso$4.00
Media$4.00
Alto$4.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 6, 2026